Clinical Benefits of Antioxidative Supplement Twendee X for Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Prospective Interventional Study

Tadokoro, Koh; Morihara, Ryuta; Ohta, Yasuyuki; Hishikawa, Nozomi; Kawano, Satoko; Matsumoto, Namiko; Nomura, Emi; Takahashi, Yoshiaki; Yamashita, Toru; Ueno, Setsuko; Wakutani, Yosuke; Takao, Yoshiki; Morimoto, Nobutoshi; Kutoku, Yumiko; Sunada, Yoshihide; Taomoto, Katsushi; Manabe, Yasuhiro; Deguchi, Kentaro; Higashi, Yasuto; Inufusa, Haruhiko; You, Fukka; Yoshikawa, Toshikazu; Greiffenclau, Markus Matuschka von

doi:10.3233/jad-190644

Cited by 30 publications

(32 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a multicenter, randomized, double-blind and placebo-controlled prospective interventional study, TwX showed a significantly higher score of the mini-mental state examination at 6 months compared with the placebo, and also a significant improvement of the Hasegawa dementia scale-revised score from baseline at 6 months, suggesting that a strong antioxidative therapy might be a useful way to prevent the conversion of MCI to AD [111].…”

Section: Twendee Xmentioning

confidence: 98%

Prevention of Cognitive Decline in Alzheimer’s Disease by Novel Antioxidative Supplements

Tadokoro

Ohta

Inufusa

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Oxidative stress plays a crucial role in Alzheimer's disease (AD) from its prodromal stage of mild cognitive impairment. There is an interplay between oxidative stress and the amyloid β (Aβ) cascade via various mechanisms including mitochondrial dysfunction, lipid peroxidation, protein oxidation, glycoxidation, deoxyribonucleotide acid damage, altered antioxidant defense, impaired amyloid clearance, inflammation and chronic cerebral hypoperfusion. Based on findings that indicate that oxidative stress plays a major role in AD, oxidative stress has been considered as a therapeutic target of AD. In spite of favorable preclinical study outcomes, previous antioxidative components, including a single antioxidative supplement such as vitamin C, vitamin E or their mixtures, did not clearly show any therapeutic effect on cognitive decline in AD. However, novel antioxidative supplements can be beneficial for AD patients. In this review, we summarize the interplay between oxidative stress and the Aβ cascade, and introduce novel antioxidative supplements expected to prevent cognitive decline in AD.

show abstract

Section: Twendee Xmentioning

confidence: 98%

Prevention of Cognitive Decline in Alzheimer’s Disease by Novel Antioxidative Supplements

Tadokoro

Ohta

Inufusa

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, recent studies have examined whether an antioxidant supplement, Twendee X (TwX), exhibits beneficial effects in a mouse model of AD with CCH [72,73]. TwX contains the antioxidants coenzyme Q10, niacin amid, L-cystine, ascorbic acid, succinic acid, fumaric acid, L-glutamine, and riboflavin [72][73][74]. One study administered TwX by oral gavage to APP23 mice, which overexpress the human APP Swedish mutant gene, that were treated with ameroid constrictors on bilateral common carotid arteries to induce CCH development [72,73].…”

Section: Preclinical Findings Obtained By Twendee X Administrationmentioning

confidence: 99%

“…On the basis of the described preclinical findings, the authors conducted a randomized, double-blind, placebo-controlled clinical trial to examine the efficacy of TwX in patients with MCI [74]. They assessed cognitive function using the Mini-Mental State Examination and Hasegawa Dementia Scale-revised scores at baseline and six months and compared the placebo (n = 37) and TwX (n = 41) groups [74]. Results revealed that cognitive function was improved in patients in the TwX group compared to the placebo group following six months of intervention [74].…”

Section: Effects Of Twx On Patients With MCImentioning

confidence: 99%

“…They assessed cognitive function using the Mini-Mental State Examination and Hasegawa Dementia Scale-revised scores at baseline and six months and compared the placebo (n = 37) and TwX (n = 41) groups [74]. Results revealed that cognitive function was improved in patients in the TwX group compared to the placebo group following six months of intervention [74]. TwX antioxidant therapy might contribute to the prevention of or delay of the progression of MCI to AD dementia [74].…”

Section: Effects Of Twx On Patients With MCImentioning

confidence: 99%

“…Results revealed that cognitive function was improved in patients in the TwX group compared to the placebo group following six months of intervention [74]. TwX antioxidant therapy might contribute to the prevention of or delay of the progression of MCI to AD dementia [74]. Notably, the mechanisms of TwX's clinical benefits have not been elucidated, in part, because the central and peripheral effects of TwX on mechanism-related indices have not been examined in these patients.…”

Section: Effects Of Twx On Patients With MCImentioning

confidence: 99%

See 2 more Smart Citations

Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer’s Disease

Tanaka

Saitô

Inoue

et al. 2020

IJMS

View full text Add to dashboard Cite

Cerebral amyloid angiopathy (CAA) is a cerebrovascular disease directly implicated in Alzheimer’s disease (AD) pathogenesis through amyloid-β (Aβ) deposition, which may cause the development and progression of dementia. Despite extensive studies to explore drugs targeting Aβ, clinical benefits have not been reported in large clinical trials in AD patients or presymptomatic individuals at a risk for AD. However, recent studies on CAA and AD have provided novel insights regarding CAA- and AD-related pathogenesis. This work has revealed potential therapeutic targets, including Aβ drainage pathways, Aβ aggregation, oxidative stress, and neuroinflammation. The functional significance and therapeutic potential of bioactive molecules such as cilostazol and taxifolin have also become increasingly evident. Furthermore, recent epidemiological studies have demonstrated that serum levels of a soluble form of triggering receptor expressed on myeloid cells 2 (TREM2) may have clinical significance as a potential novel predictive biomarker for dementia incidence. This review summarizes recent advances in CAA and AD research with a focus on discussing future research directions regarding novel therapeutic approaches and predictive biomarkers for CAA and AD.

show abstract

Role of Antioxidants, and Lifestyle in Managing Brain Disorders Oxidative Stress Biomarkers and Antioxidant Treatments in Brain Diseases

Özcan,

Karahan,

Konuk

2023

Food Bioactive Ingredients

View full text Add to dashboard Cite

Clinical Benefits of Antioxidative Supplement Twendee X for Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Prospective Interventional Study

Cited by 30 publications

References 39 publications

Prevention of Cognitive Decline in Alzheimer’s Disease by Novel Antioxidative Supplements

Prevention of Cognitive Decline in Alzheimer’s Disease by Novel Antioxidative Supplements

Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer’s Disease

Role of Antioxidants, and Lifestyle in Managing Brain Disorders Oxidative Stress Biomarkers and Antioxidant Treatments in Brain Diseases

Contact Info

Product

Resources

About